Peter Lönnecke

Dr. Peter Lönnecke

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2019 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
ABAntonio Buzharevski
Antonio Buzharevski
SPSvetlana Paskas
Svetlana Paskas
MSMenyhárt‐Botond Sárosi
Menyhárt‐Botond Sárosi
MLMarkus Laube
Markus Laube
PLPeter Lönnecke
Peter Lönnecke
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins

30 December 2011 in Inorganic Chemistry
Verified
Journal Article
Closed access
AKAlexander N. Kornev
Alexander N. Kornev
VSVyacheslav V. Sushev
Vyacheslav V. Sushev
YPYulia S. Panova
Yulia S. Panova
NBNatalia V. Belina
Natalia V. Belina
OLOlga V. Lukoyanova
Olga V. Lukoyanova
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins

14 June 2019 in Dalton Transactions
Verified
Journal Article
Open access
PDF file
MKMartin Kellert
Martin Kellert
DWDennis J. Worm
Dennis J. Worm
PHPaul Hoppenz
Paul Hoppenz
MSMenyhárt B. Sárosi
Menyhárt B. Sárosi
PLPeter Lönnecke
Peter Lönnecke
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins
Based on a modular combination of s-triazine, the well-known 9-mercapto-1,7-dicarba-closo-dodecaborane(12) and commercially available carboxylic acids, namely thioglycolic acid, glycine, and Nα-Boc-L-lysine, several carboxylic acid derivatives were synthesised and fully characterised. The thioglycolic acid derivative was introduced into a peptide hormone by solid phase peptide synthesis. High activity and selective internalisation into peptide receptor-expressing cells was observed. With a very high boron content of twenty boron atoms, these derivatives are interesting as selective Boron Neutron Capture Therapy (BNCT) agents.

17 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AKAleksandr Kazimir
Aleksandr Kazimir
BSBenedikt Schwarze
Benedikt Schwarze
PLPeter Lönnecke
Peter Lönnecke
SJSanja Jelača
Sanja Jelača
SMSanja Mijatović
Sanja Mijatović
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins
The luminal A-subtype of breast cancer, where the oestrogen receptor α (ERα) is overexpressed, is the most frequent one. The prodrug tamoxifen (1) is the clinically used agent, inhibiting the ERα activity via the formation of several active metabolites, such as 4-hydroxytamoxifen (2) or 4,4′-dihydroxytamoxifen (3). In this study, we present the tamoxifen derivative 4-[1,1-bis(4-methoxyphenyl)but-1-en-2-yl]-2,2′-bipyridine (4), which was combined with platinum or palladium dichloride, the former a well-known scaffold in anticancer treatment, to give [PtCl2(4-κ2N,N′)] (5) or [PdCl2(4-κ2N,N′] (6). To prevent fast exchange of weakly coordinating chlorido ligands in aqueous solution, a bulky, highly stable and hydrophobic nido-carborate(−2) ([C2B9H11]2−) was incorporated. The resulting complexes [3-(4-κ2N,N′)-3,1,2-PtC2B9H11] (7) and [3-(4-κ2N,N′)-3,1,2-PdC2B9H11] (8) exhibit a dramatic change in electronic and biological properties compared to 5 and 6. Thus, 8 is highly selective for triple-negative MDA-MB-231 cells (IC50 = 3.7 μM, MTT test), while 7 is completely inactive against this cell line. The observed cytotoxicity of compounds 4–6 and 8 against this triple-negative cell line suggests off-target mechanisms rather than only ERα inhibition, for which these compounds were originally designed. Spectroscopic properties and electronic structures of the metal complexes were investigated for possible explanations of the biological activities.

24 November 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
RKRobert Kuhnert
Robert Kuhnert
MSMenyhárt‐Botond Sárosi
Menyhárt‐Botond Sárosi
SGSven George
Sven George
PLPeter Lönnecke
Peter Lönnecke
BHBettina Hofmann
Bettina Hofmann
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins

26 March 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
IPIvana Predarska
Ivana Predarska
MSMohamad Saoud
Mohamad Saoud
IMIbrahim Morgan
Ibrahim Morgan
PLPeter Lönnecke
Peter Lönnecke
Goran KaluđerovićGoran Kaluđerović
Goran Kaluđerović
Evamarie Hey-HawkinsEvamarie Hey-Hawkins
Evamarie Hey-Hawkins
Organotin(IV) carboxylates are a class of compounds explored as alternatives to platinum-containing chemotherapeutics due to propitious in vitro and in vivo results, and distinct mechanisms of action. In this study, triphenyltin(IV) derivatives of non-steroidal anti-inflammatory drugs (indomethacin (HIND) and flurbiprofen (HFBP)) are synthesized and characterized, namely [Ph3Sn(IND)] and [Ph3Sn(FBP)]. The crystal structure of [Ph3Sn(IND)] reveals penta-coordination of the central tin atom with almost perfect trigonal bipyramidal geometry with phenyl groups in the equatorial positions and two axially located oxygen atoms belonging to two distinct carboxylato (IND) ligands leading to formation of a coordination polymer with bridging carboxylato ligands. Employing MTT and CV probes, the antiproliferative effects of both organotin(IV) complexes, indomethacin, and flurbiprofen were evaluated on different breast carcinoma cells (BT-474, MDA-MB-468, MCF-7 and HCC1937). [Ph3Sn(IND)] and [Ph3Sn(FBP)], unlike the inactive ligand precursors, were found extremely active towards all examined cell lines, demonstrating IC50 concentrations in the range of 0.076–0.200 µM. Flow cytometry was employed to examine the mode of action showing that neither apoptotic nor autophagic mechanisms were triggered within the first 48 h of treatment. However, both tin(IV) complexes inhibited cell proliferation potentially related to the dramatic reduction in NO production, resulting from downregulation of nitric oxide synthase (iNOS) enzyme expression.